Commentary
Biomarkers and stage II colorectal cancer therapy
Abstract
According to the American Cancer Society, colorectal cancer (CRC) is the third leading cause of cancer related death in the United States among men and women. Despite a steady decrease in mortality rates, CRC is still estimated to result in 49,190 deaths during 2016 (1).
